23 December 2015 - Sanofi announced today that it has submitted a NDA to the U.S. FDA for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.

For more details, go to: http://en.sanofi.com/NasdaQ_OMX/local/press_releases/sanofi_submits_new_drug_applic_1975672_23-12-2015!07_00_00.aspx